<DOC>
	<DOCNO>NCT01912339</DOCNO>
	<brief_summary>To evaluate safety efficacy Rezūm System assess effect urinary symptom secondary benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Safety Efficacy Study Treatment BPH ( Enlarged Prostate )</brief_title>
	<detailed_description>This study prospective , control , randomize single blind clinical trial subject benign prostatic hyperplasia , allow interim analysis sample size adjustment . Subjects first randomize 2:1 proportion favor Treatment arm . Subjects Control arm allow crossover Rezūm treatment 3-month follow-up examination .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>1 . Male subject &gt; 50 year age symptomatic BPH . 2. International Prostate Symptom Score ( IPSS ) score ≥ 13 . 3 . Peak urinary flow rate ( Qmax ) : ≥ 5ml/sec ≤ 15 ml/sec minimum void volume ≥ 125 ml . 4 . Postvoid residual ( PVR ) ≤250 ml . 5 . Prostate volume &gt; 30 ≤ 80 gm . 1 . History clinically significant congestive heart failure ( i.e . NYHA Class III IV ) . 2 . History diabetes control stable dose medication past three month . Patients Hemoglobin A1c &lt; 8.0 % allow . 3 . History significant respiratory disease hospitalization disease require . 4 . History immunosuppressive condition ( e.g. , AIDS , posttransplant ) . 5 . Cardiac arrhythmia control medication medical device . 6 . An episode unstable angina pectoris , myocardial infarction , transient ischemic attack , cerebrovascular accident within past six month . 7 . Any significant medical history would pose unreasonable risk make subject unsuitable study . 8 . Presence penile implant stent ( ) urethra prostate . 9 . Any prior invasive prostate intervention ( e.g. , radio frequency ( RF ) ablation , balloon , microwave , laser ) surgical intervention prostate . 10 . Currently enrol preapproval investigational study USA ( apply longterm postmarket study unless study might clinically interfere current study endpoint ( e.g. , limit use studyrequired medication , etc. ) ) . 11 . History confirm malignancy cancer prostate bladder , however , high grade PIN acceptable . 12 . History cancer nongenitourinary system consider cure ( except basal cell squamous cell carcinoma skin ) . A potential participant consider cured evidence cancer within five year randomization . 13 . Previous pelvic irradiation radical pelvic surgery . 14 . Diagnosed active Lyme Disease ( borreliosis ) . 15 . PSA &gt; 10 ng/ml unless prostate cancer rule biopsy . If PSA &gt; 2.5 ng/ml ≤ 10 ng/ml free PSA &lt; 25 % , prostate cancer subject must be/had rule negative biopsy prior enrollment . 16 . Has undergone prostate biopsy within 60 day prior treatment date imminent need surgery . 17 . Previous rectal surgery ( hemorrhoidectomy ) know history rectal disease . 18 . Active urinary tract infection culture within 7 day treatment two document independent urinary tract infection type past 6 month . 19 . Verified bacterial prostatitis within last 12 month document culture nonbacterial prostatitis within last 5 year . 20 . Active history epididymitis within past 3 month . 21 . Neurogenic bladder , sphincter abnormality , poor detrusor muscle function . 22 . Diagnosed suspected primary neurologic condition multiple sclerosis Parkinson 's disease neurological disease know affect bladder function , sphincter function poor detrusor muscle function . 23 . Urethral stricture , bladder neck contracture , unusual anatomy muscle spasm would prevent introduction use device . 24 . Diagnosed bladder , urethral ureteral stone active stone passage past 6 month . Stones know kidney stable period exceed 3 month permissible . 25 . Postvoid residual ( PVR ) &gt; 250 ml . 26 . Diagnosed suspect bleed disorder , coagulopathies . 27 . Use antiplatelet anticoagulant medication except low dose aspirin ( ≤81 mg/day ) within 10 day prior treatment . 28 . Visible hematuria subject urine sample without know contribute factor . 29 . Subject interested maintaining fertility . 30 . Use betablockers , anticonvulsant , antispasmodic dose stable . ( Stable dose define medication dose last six month ) . 31 . At time baseline assessment , absence qualify exception , subject use use follow medication , unable unwilling discontinue use medication prescribe washout period : 1 . Use antihistamine within 1 week treatment unless document evidence stable dose last 6 month ( dose change ) . 2 . Use alpha blocker BPH anticholinergic cholinergics ( except topical anti cholinergic eye drop ) , within 4 week baseline assessment . 3 . Use Type II , 5alpha reductase inhibitor ( e.g. , finasteride ( Proscar , Propecia ) within 3 month baseline assessment . 4 . Use dual 5alpha reductase inhibitor ( e.g. , dutasteride ( Avodart ) ) within 6 month baseline assessment . 5 . Use estrogen , drugproducing androgen suppression , anabolic steroid within 3 month baseline assessment . 6 . Use daily dose PD5 Inhibitors ( e.g.Viagra , Levitra Cialis ) within 4 week baseline assessment . 32 . Subjects incidence spontaneous urinary retention either treat indwell transurethral catheter suprapubic catheter six month prior baseline . A provoked episode resolve still admissible . 33 . Compromised renal function define serum creatinine &gt; 2.0 mg/dl . 34 . Inability provide legally effective Informed Consent Form ( ICF ) and/or comply require followup requirement . 35 . Any cognitive psychiatric condition interferes precludes direct accurate communication study investigator regard study affect ability complete study quality life questionnaire .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hyperlasia</keyword>
	<keyword>Retention</keyword>
	<keyword>Prostate</keyword>
</DOC>